Two Sigma Advisers
SUPN icon

Two Sigma Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Two Sigma Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,500
Closed -$884K – 2610
2025
Q3 		$884K Buy
18,500
+10,000
+118% +$403K ﹤0.01% 1522
2025
Q2 		$268K Sell
8,500
-24,800
-74% -$795K ﹤0.01% 2006
2025
Q1 		$1.09M Buy
33,300
+25,500
+327% +$904K ﹤0.01% 1436
2024
Q4 		$282K Buy
7,800
+1,000
+15% +$35.2K ﹤0.01% 2003
2024
Q3 		$212K Sell
6,800
-23,800
-78% -$743K ﹤0.01% 2043
2024
Q2 		$819K Sell
30,600
-112,700
-79% -$3.27M ﹤0.01% 1655
2024
Q1 		$4.89M Sell
143,300
-83,800
-37% -$2.5M 0.01% 789
2023
Q4 		$6.57M Buy
227,100
+31,000
+16% +$822K 0.02% 694
2023
Q3 		$5.41M Sell
196,100
-83,300
-30% -$2.54M 0.01% 692
2023
Q2 		$8.4M Sell
279,400
-30,300
-10% -$1.06M 0.02% 564
2023
Q1 		$11.2M Buy
309,700
+93,700
+43% +$3.6M 0.03% 520
2022
Q4 		$7.7M Buy
216,000
+118,700
+122% +$4.13M 0.02% 595
2022
Q3 		$3.29M Buy
97,300
+83,000
+580% +$2.7M 0.01% 937
2022
Q2 		$414K Sell
14,300
-16,400
-53% -$470K ﹤0.01% 2003
2022
Q1 		$992K Buy
30,700
+8,400
+38% +$258K ﹤0.01% 1642
2021
Q4 		$650K Buy
22,300
+9,500
+74% +$288K ﹤0.01% 1778
2021
Q3 		$341K Sell
12,800
-74,000
-85% -$1.99M ﹤0.01% 2064
2021
Q2 		$2.67M Sell
86,800
-146,000
-63% -$4.48M 0.01% 1158
2021
Q1 		$6.09M Buy
232,800
+89,600
+63% +$2.51M 0.02% 768
2020
Q4 		$3.6M Sell
143,200
-99,500
-41% -$2.14M 0.01% 960
2020
Q3 		$5.06M Sell
242,700
-173,500
-42% -$3.94M 0.01% 764
2020
Q2 		$9.88M Buy
416,200
+36,400
+10% +$804K 0.03% 560
2020
Q1 		$6.83M Buy
379,800
+250,200
+193% +$5.26M 0.03% 612
2019
Q4 		$3.07M Sell
129,600
-300
-0.2% -$7.29K 0.01% 1032
2019
Q3 		$3.57M Sell
129,900
-199,300
-61% -$5.91M 0.01% 891
2019
Q2 		$10.9M Buy
329,200
+97,000
+42% +$3.32M 0.03% 560
2019
Q1 		$8.14M Buy
+232,200
New +$8.64M 0.02% 669
2018
Q3 		– Sell
-11,600
Closed -$694K – 2389
2018
Q2 		$694K Buy
11,600
+4,600
+66% +$238K ﹤0.01% 1782
2018
Q1 		$321K Buy
+7,000
New +$292K ﹤0.01% 1982
2017
Q3 		– Sell
-18,400
Closed -$793K – 2345
2017
Q2 		$793K Buy
18,400
+200
+1% +$7.12K ﹤0.01% 1625
2017
Q1 		$570K Buy
18,200
+300
+2% +$8.04K ﹤0.01% 1837
2016
Q4 		$452K Buy
17,900
+1,700
+10% +$38K ﹤0.01% 1922
2016
Q3 		$401K Buy
+16,200
New +$367K ﹤0.01% 1768
2015
Q2 		– Sell
-36,600
Closed -$442K – 2060
2015
Q1 		$442K Buy
+36,600
New +$346K ﹤0.01% 1406

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's SUPN Position: Q4 2025 in Review

Two Sigma Advisers sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 18,500 shares — an estimated $884K sold.

Two Sigma Advisers first reported a position in SUPN in Q1 2015 and held it in 34 quarters. The position peaked at $11.2M in Q1 2023. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Two Sigma Advisers reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 18,500 Supernus Pharmaceuticals shares in Q4 2025, an estimated $884K.
  • Two Sigma Advisers first reported a position in Supernus Pharmaceuticals in Q1 2015 and held it in 34 quarters.
  • Two Sigma Advisers's Supernus Pharmaceuticals position peaked at $11.2M in Q1 2023.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.